World leaders in their fields
To drive the development of Apta-1 in the most cost-effective manner, while keeping set schedules, Aptahem collaborates with various consultants and contract research laboratories around the world. Aptahem’s partners are world leaders in their fields, and they meet the, Good Laboratory Practice (GLP) and Good Manufacturing Practice, (GMP) requirements required by Aptahem.
Axolabs is developing a bioanalytical method for analyzing Aptahem’s lead candidate Apta-1.
Accelera is performing the non-clinical toxicology program on Aptahem’s lead candidate Apta-1.
Hooke Laboratories work together with Aptahem in in vivo animal models.
Seattle Children’s Research Institute will together with Aptahem study the effect of Apta-1 treatment on infectious sepsis animal models and also in in vitro studies.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.2 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm will develop the pharmaceutical formulation of Apta-1 for the first clinical trial.